Severity of COVID-19 Infection in ACEI/ARB Users in Two Saudi Public Specialty Hospitals: Retrospective Cohort Study

Ahmed A. Alrashed
King Fahd Medical City

Tahir Khan
The institute of Pharmaceutical Science (IPS) of University of Veterinary and Animal Sciences, Lahore

Noara Alhusseini
Alfaisal University

Syed Mohammed Asdaq (sasdag@mcst.edu.sa)
AlMaarefa University

Mushira Enani
King Fahd Medical City

Bandar Alosaimi
King Fahd Medical City

Nada Alkhani
King Fahd Medical City

Yahya Mohzari
King Saud Medical City

Maram Alghalbi
Prince Sultan Military Medical City

Wafa Alfahad
Prince Sultan Military Medical City

Mona Alanazi
Prince Mohammed bin Abdulaziz Hospital

Asma Albujaidyia
Prince Mohammed bin Abdulaziz Hospital

Amal Ben-Akresh
Prince Sultan Military Medical City

Malak Almutairi
AlMaarefa University

Ivo Abraham
University of Arizona

Ahmad Alamer
University of Arizona

Research Article

Keywords: Angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, COVID-19, mortality, disease severity, hospital admission, Saudi Arabia.

DOI: https://doi.org/10.21203/rs.3.rs-113824/v1

License: © ️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The uncertainty about COVID-19 outcomes in angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) users continues with contradictory findings. The aim of this study was to determine the effect of ACEI/ARB use in patients with severe COVID-19.

Methods: This retrospective cohort study was done in two Saudi public specialty hospitals designated as COVID-19 referral facilities. We included 354 patients with confirmed diagnosis of COVID-19 between April and June 2020, of which 146 were ACEI/ARB users and 208 were non-ACEI/ARB users. For confounders, we conducted a multivariate logistic regression and a sensitivity analyses using propensity score matching (PSM) and Inverse propensity score weighting (IPSW) for high risk patient subsets.

Results: Compared to non-ACEI/ARB users, ACEI/ARB users had an eight-fold higher risk of developing critical or severe COVID-19 (OR=8.25, 95%CI=3.32-20.53); a nearly 7-fold higher risk of intensive care unit (ICU) admission (OR=6.76, 95%CI=2.88-15.89) and a nearly 5-fold higher risk of requiring noninvasive ventilation (OR=4.77, 95%CI=2.15-10.55). Patients with diabetes, hypertension, and/or renal disease had a five-fold higher risk of severe COVID-19 disease (OR=5.40, 95%CI=2.0-14.54). These results were confirmed in the PSM and IPSW analyses.

Conclusion: In general, but especially among patients with hypertension, diabetes, and/or renal disease, ACEI/ARB use is associated with a significantly higher risk of severe or critical COVID-19 disease, and ICU care.

Introduction

Coronavirus disease 2019 (COVID-19) is pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. It emerged in Wuhan, the largest city in Hubei Province, China and rapidly spread to become a worldwide pandemic [2]. The World Health Organization (WHO) reported as of 31 August 2020 more than 25 million confirmed cases of COVID-19 and more than 800,000 death cases globally [3]. The virus is transmitted through respiratory droplets or aerosols and direct contact. The disease is characterized by a wide range of symptoms, and patients may experience mild, severe, or critical illness [4]. The overall mortality rate in various countries ranges from 2% to 13% [5].

Risk factors associated with the clinical severity of COVID-19 include age (especially >75 years old), obesity, selected medications, and comorbidities such as hypertension, diabetes, and cardiovascular disease [6-10]. Noteworthy is the frequent presence of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) in these patients’ pharmacological treatment. It has been hypothesized that exposing patients to ACEI/ARB may increase the expression of ACE2 by a negative feedback mechanism, thus facilitating the binding process of coronavirus to epithelial cells of the kidney, intestine, lung, and blood vessels [11] and increasing the risk of developing severe and fatal COVID-19 disease [12-14]. Clinical research evidence to date has been equivocal, especially in terms of identifying differentiating factors that may mediate the ACEI/ARB and COVID-19 severity relationship [15-17].

In the case of Saudi Arabia, we have a young developing country with a median age of 30.8 years burdened with comorbid diseases [18]. The Saudi Arabia’s healthcare system is mainly funded by the public sector through the Ministry of Health (MOH) which serves 23 million people. Though at different levels, critical care services are provided in primary, secondary, and tertiary/specialty hospitals; with complex cases being referred to tertiary/specialty hospitals that are well equipped with specialized intensive care units (ICU) and highly trained intensivists [19]. Regarding comorbid disease in the Saudi general population and in spite of extensive healthcare resources, the WHO ranks Saudi Arabia 7th in the world in terms of rates of diabetes with an estimated 7 million people affected, followed by hypertension (26.1%), and rapidly emerging because of its association with both conditions, chronic kidney disease (6%) [20-22]. Studies link the development of these diseases to ACE insertion/deletion (I/D) polymorphism in certain populations including Saudis [23-26].

The uncertainty about COVID-19 outcomes in ACE/ARB users may be a function of how patients with diabetes, hypertension, and/or chronic renal disease are clinically compromised and therefore more susceptible to severe COVID-19 disease. A systematic review concluded that patients with diabetes, hypertension, and chronic renal disease had an increased mortality risk in the setting of Middle Eastern respiratory syndrome (MERS) coronavirus infection (a coronavirus closely related to SARS-CoV-2 that originated in Saudi Arabia in 2012) [27]. We report here on a retrospective real-world clinical study in two public tertiary/specialty hospitals to which severe COVID-19 cases were referred to assess the association of ACEI/ARB and clinical severity of COVID-19. Severity of COVID-19 disease in ACE/ARB users was based on the following variables: ICU admission, non-invasive and invasive mechanical ventilation, in-hospital mortality, and hospital length of stay. In addition to outcomes observed in the overall population of referred patients, we also evaluated severity outcomes for high risk patients with diabetes, hypertension and/or renal disease.

Methods

Study Design and Study Setting

This retrospective was conducted in the tertiary specialty referral hospitals known as King Fahad Medical City (KFMC; 1200 beds) and Prince Mohammed Bin Abdulaziz hospital (PMAH; 500 beds), both in Riyadh, Saudi Arabia. The Institutional Review Boards at KFMC and PMAH (IRB 20-200) approved the study. All methods were performed in accordance with the relevant guidelines and regulations, Institutional review boards of both KFMC and PMAH waived informed consent since it was an exempt study conducting a retrospective analysis.

Participant selection

Lists of discharged or dead COVID-19 patients were obtained from the health informatics officer and categorized into ACEI/ARB users and ACEI/ARB non-users based on their medication history. Inclusion criteria were age >18 years admitted at KFMC or PMAH from April to June 2020, being treated with ACE/ARB inhibitors 6 months before and continued during hospital admission and after discharge for any indications such as hypertension, stroke, heart failure,
myocardial infarction, diabetes mellitus, chronic kidney disease or nephrotic syndrome (criteria only for ACEI/ARB users); and SARS-CoV-2 infection confirmed by real-time polymerase chain reaction (RT-PCR) from nasopharyngeal swab for inclusion. Patients were excluded if pregnant, incomplete medical records due to patients being transferred recently from other hospitals, or unknown medications history.

Data Collection

Data were extracted manually from electronic health records (Cortrex system and HIM system in KFMC, and Cerner Systems in PMAH) by a trained team and included demographic and anthropometric variables such as age, height, weight, body mass index (BMI), class of obesity; medical history of hypertension, diabetes, asthma, cardiovascular disease (including coronary artery disease, heart failure), renal disease (chronic kidney disease or nephrotic syndrome); COVID-19 treatment regimen; use of ACE/ARB; spectrum of illness severity; need for ICU admission; need for non-invasive ventilation (NIV) (e.g., face mask, nasal cannula, nasal mask, or helmet); need for invasive mechanical ventilation (MV); in hospital-death; and length of hospitalization.

COVID-19 Spectrum of Severity definitions

We defined the spectrum of disease severity according to the WHO [28]. Mild illness was defined as uncomplicated upper respiratory tract viral infection and may have non-specific symptoms such as fever, fatigue, cough, anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Moderate illness was the development of non-severe pneumonia that does not require supplemental oxygen. Severe pneumonia was defined as fever plus symptoms ≥1 of the following: respiratory rate ≥30/min, dyspnea, respiratory distress, SpO2 ≤93% on room air, PaO2/FiO2 ratio <300 or lung infiltrate >50% of lung field within 24-48hr. Critical illness manifested by symptoms ≥1 of the following: acute respiratory distress syndrome (ARDS), septic shock, altered consciousness, or multi-organ Failure.

Study Outcomes

The primary outcome was COVID-19 severity classified as mild, moderate, severe, or critical according to the WHO classification in ACEI/ARB users as compared to non-ACEI/ARB users. Secondarily, we evaluated the need of ICU admission, NIV and MV, in-hospital death, and length of hospital stay in patients on ACEI/ARB as compared to non-ACEI/ARB users. We also assessed COVID-19 severity (severe or critical) in patients with (1) one of the three comorbidities of interest (diabetes, hypertension or renal disease); (2) both diabetes and hypertension; (3) diabetes only; and (4) hypertension only.

Statistical Analysis

Using R Core Team (2020) software (R Foundation for Statistical Computing, Version 4.0.1, Vienna, Austria), continuous data were expressed as mean with standard deviation (±SD) or median with interquartile range (IQR). If the normality assumption was met using normal Q-Q plot and the Shapiro–Wilk test, we used the Student's t-test for group comparisons; if not met, we used the Mann-Whitney. Categorical data were reported as frequencies and percentages and analyzed either using the Chi-square test for nxm tables or Fisher's exact test for 2x2 tables group comparisons. To obtain odds ratios, we performed a multivariable logistic regression model adjusting for the confounders (either P<0.3 in a univariable logistic regression model or clinically important confounders) of age, sex, BMI, diabetes, hypertension, renal disease, number of comorbidities (diabetes, hypertension, cardiovascular disease [heart failure/coronary artery disease], stroke, renal disease, asthma and obesity) and COVID-19 treatment regimen. All statistical inferences were drawn with 95% confidence intervals with P<0.05. Bonferroni adjustments were applied to control for multiplicity [29].

Sensitivity analyses

Propensity score-matched analysis

Propensity score-matched (PSM) procedure was implemented to the dataset. Using Matchit package in R [30], the treatment assignment was modelled with a multivariable logistic regression with the following specifications: nearest neighbor 1:3 with replacement and a caliper of 0.1. Multiple models were fitted and compared using the "cobalt" package to plot propensity score distributional mirror diagrams and standardized mean difference (SMD) before and after matching. The SMD check for data balance is an indicated statistical procedure to judge the quality of matched data rather than means or standard deviations of the matched subjects[31]. In our case we considered values of SMD ≤0.1 to be indicative of adequate balance and fruitful matching. We carefully examined models in which we evaluated different interaction terms. The final model was then selected based on the above criterion. The following covariates were included in final model: age, BMI, diabetes, hypertension, renal disease and number of comorbidities. We illustrated the propensity score distribution (prior matching was also evaluated using mirror diagram and the love plot for SMD distribution) (see Supplementary Fig. S1 and Fig. S2).

Inverse propensity score weighting (IPSW)

In addition to PSM, we considered a secondary sensitivity analysis for high risk patients (diabetes, hypertension or renal disease). We limited the analysis to the severity outcome to avoid a multiplicity problem. In this technique, we used "WeightIt" and "ipw" packages in R to calculate inverse propensity weights[32] [33]. The following covariates were considered in the IPSW analysis: age, gender, diabetes, hypertension, renal disease, cardiovascular disease, body mass index, and asthma and number of comorbidities. For specifics, see Fig S3 on covariates selected and balance distribution. Again, various models were fitted and toughly tested before selecting the best model for each data subsets. Following the recommendation from Desai et al [34], the estimand was the average treatment effect. Stabilized weights were utilized in our analysis and then we examined weights with plots and summary statistics to prevent variance inflation from extreme weights. Love plots for SMD distribution presented in supplementary. Lastly, we fitted a structural causal model using "Survey" package to obtain robust variance estimation (sandwich type).

Results
From April to June 2020, a total of 532 confirmed cases of COVID-19 disease were admitted to the KFMC and PMAH hospitals. Of these, 178 patients were excluded from analysis as they did not meet eligibility criteria. A total of 146 patients on ACEI/ARB and 208 were non-ACEI/ARB users included in multivariable logistic regression analysis. Propensity score matching yielded 145 ACEI/ARB users and 63 patients' non-ACEI/ARB users (Figure 1).

The mean (±SD) age of the ACEI/ARB group was 56.3 (11.9), BMI was 28.8 kg/m² (6.3) and 78.1% were men, compared with 40.2 years (11.5), BMI of 27.4 kg/m² (7.4) and 81.7% were men in non-ACEI/ARB group (Table 1). Rates of diabetes of 41.6%, hypertension of 34.5%, and renal disease of 7.3% were observed in the total sample. The propensity score matching controlling for the selected covariates was balanced [Table S1; see also Supplementary Figure S1 and Figure S2 (love plot) for propensity scores distribution and balance of covariates, respectively]. Covariate balance for IPSW analysis presented in supplementary (Figure S3).

### Table 1. Patients' baseline characteristics

| Baseline                        | ACEI/ARB (intervention) | Non-ACEI/ARB (control) | Total | P value |
|---------------------------------|-------------------------|------------------------|-------|---------|
| Age, mean ±SD                   | 56.36 (11.9)            | 40.29 (11.6)           | 46.9 (14.11) | < 0.001 |
| Male, n (%)                     | 114 (78.1)              | 170 (81.7)             | 284 (80.2) | 0.396   |
| BMI, mean ±SD                   | 28.8 (6.3)              | 27.4 (7.4)             | 28 (6.9)    | 0.059   |
| Obesity, n (%)                  | 41 (28.1)               | 40 (19.2)              | 81 (22.9)   | 0.051   |
| Hypertension, n (%)             | 123 (84.2)              | 22 (10.6)              | 145 (41.0)  | < 0.001 |
| Diabetes, n (%)                 | 98 (67.1)               | 42 (20.2)              | 140 (39.5)  | < 0.001 |
| Cardiovascular disease (HF,CAD), n (%) | 42 (28.8)            | 5 (2.4)                | 47 (13.3)   | < 0.001 |
| Stroke, n (%)                   | 3 (2.1)                 | 1 (0.5)                | 4 (1.1)     | 0.168   |
| Renal disease, n (%)            | 17 (11.6)               | 9 (4.3)                | 26 (7.3)    | 0.009   |
| Asthma, n (%)                   | 24 (11.5)               | 15 (10.3)              | 39 (11.3)   | 0.708   |
| Current use of NSAIDs, n (%)    | 24 (16.4)               | 27 (13.0)              | 51 (14.4)   | 0.362   |
| Number of comorbidities*, Median (IQR) | 3.322 (1.050)         | 1.688 (0.990)          | 2.362 (1.295) | < 0.001 |
| COVID-19 regimen                |                         |                       |       |         |
| Supportive Care                 | 105 (71.4)              | 159 (76.4)             | 264 (74.6)  |         |
| Lopinavir/ritonavir             | 2 (1.4)                 | 0 (0)                  | 2 (0.6)     |         |
| Favipravir                      | 2 (1.4)                 | 0 (0)                  | 2 (0.6)     |         |
| Hydroxychloroquine+Azithromycin| 29 (19.9)               | 39 (18.8)              | 68 (19.2)   |         |
| Hydroxychloroquine              | 8 (5.5)                 | 10 (4.8)               | 18 (5.1)    |         |

*Comorbidities include: diabetes, hypertension, cardiovascular disease (heart failure/coronary artery disease), stroke, renal disease, asthma and obesity.

IQR: Interquartile range. SD: Standard deviations. ACEI: Angiotensin-converting-enzyme inhibitors. ARBs: Angiotensin II receptor blockers. COVID-19: Coronavirus disease 2019. HF: heart failure. CAD: coronary artery disease

**Samples**

From crude counts and percentages (Table 2), the two multivariable logistic regression models estimated the adjusted odds ratios for the unmatched and matched data for the entire sample. Compared to non-ACEI/ARB users, patients treated with ACEI/ARB were at significantly higher risk of developing severe/critical COVID-19 compared to non-users (OR=8.25, 95%CI=3.32-20.53, P<0.001); being admitted to the ICU (OR= 6.76, 95%CI=2.88-15.89, P<0.001); and requiring noninvasive ventilation (OR=4.77, 95%CI=2.15-10.55, P<0.001); but at statistically equal risk of requiring mechanical ventilation or in-hospital death. The results remained significant after adjusting for multiplicity and were confirmed in the PSM sensitivity analysis. Cases classified as mild-moderate category were higher among non-ACEI/ARB users (P<0.001; Supplementary Table S2). All other comparisons between ACEI/ARB users and non-users on the outcomes of interest were statistically non-significant. Of note, age was independently associated with an increased need of non-invasive ventilation in the multivariable logistic regression (OR=1.03, 95%CI=1.00-1.06, P=0.036).
Table 2. Adjusted odds ratio for clinical outcomes among users and non-users of ACEI/ARB

| Variable                  | ACEI/ARB (unmatched) | Non-ACEI/ARBs (unmatched) | Adjusted odds ratio† (95% CI) | P value | Bonferroni adjustmenta | ACEI/ARB (matched) | Non-ACEI/ARB (matched) | Adjusted odds ratio‡ (95% CI) | P value | Bonferroni adjustmenta |
|---------------------------|----------------------|---------------------------|-------------------------------|---------|------------------------|-------------------|----------------------|-------------------------------|---------|------------------------|
| Severe or critical*, n (%)| 126 (86.3)           | 67 (32.2)                 | 8.25 (3.32 - 20.53)           | <0.001  | <0.001                 | 125 (86.2)       | 30 (47.6)            | 5.55 (2.41 - 12.80)          | <0.001  | <0.001                 |
| ICU admission, n (%)      | 74 (50.7)            | 23 (11.1)                 | 6.76 (2.88 - 15.89)           | <0.001  | <0.001                 | 73 (50.3)        | 11 (17.5)            | 4.98 (2.02 - 12.21)          | <0.001  | 0.002                  |
| Noninvasive Ventilation, n (%) | 103 (70.5)        | 54 (26.0)                 | 4.77 (2.15 - 10.55)           | <0.001  | <0.001                 | 103 (71.0)       | 25 (39.7)            | 3.57 (1.68 - 8.80)           | 0.001   | 0.005                  |
| Mechanical ventilation, n (%) | 32 (21.9)            | 13 (6.2)                  | 1.68 (0.58 - 4.83)            | 0.337   | 1.000                  | 31 (21.4)        | 6 (9.5)              | 1.63 (0.53 - 4.96)           | 0.358   | 1.000                  |
| In-hospital death, n (%)  | 3 (2.1)              | 2 (1.0)                   | 0.35 (0.03 - 4.63)            | 0.427   | 1.000                  | 3 (2.1)          | 2 (3.2)              | 0.48 (0.05 - 4.49)           | 0.521   | 1.000                  |

*Severe or critical defined according to WHO severity definition. ICU: Intensive care unit.
†Odds ratio adjusted using logistic regression model with the following variables: age, sex, BMI, diabetes, hypertension, renal disease, number of comorbidities (that includes diabetes, hypertension, cardiovascular disease (heart failure/coronary artery disease), stroke, renal disease, asthma and obesity) and inpatient COVID-19 regimen.
‡Odds ratios adjusted using propensity score matching model
a For multiplicity correction, Bonferroni method was used to adjust the P values

Diabetes, Hypertension or Renal disease

Patients with diabetes, hypertension, or renal disease on ACEI/ARB therapy were found to have significantly higher COVID-19 severity as compared to non-ACEI/ARB users (72.2% vs 27.8%) with OR 5.34[95% CI=1.87-15.30] (Table 3). Patients with diabetes and hypertension, diabetes alone or hypertension on ACEI/ARB had a higher severity when compared to non-ACEI/ARB users (Table 3. After adjusting for multiplicity, results remained significant except for the presence of diabetes alone. The PSM sensitivity analyses confirmed these results except for the presence of hypertension and diabetes together. IPSW agrees with the PSM results in which we found significant severity outcome in the following subset of patients: presence of diabetes, hypertension or renal disease (OR 1.44[95% CI=1.18-1.76]), diabetes alone (OR 1.33[95% CI=1.04-1.71]) and hypertension alone (OR 1.47[1.13-1.91]). IPSW results shown in Table 4.
| Population          | ACEI/ARB (unmatched) n, (%) | Non-ACEI/ARB (unmatched) n, (%) | Adjusted odds ratio† (95% CI) | $P$ value | Adjustment‡ | ACEI/ARB (matched) n, (%) | Non-ACEI/ARB (matched) n, (%) | Adjusted odds ratio‡ (95% CI) | $P$ value | Adjustment‡ |
|---------------------|-----------------------------|---------------------------------|-------------------------------|-----------|------------|-----------------------------|--------------------------------|-------------------------------|-----------|------------|
| **DM or HTN or Renal disease** |                             |                                 |                               |           |            |                             |                                 |                               |           |            |
| unmatched (n=187)   | 135(72.2)                   | 52(27.8)                        | -                             | -         | -          | 134(77.5)                   | 39(22.5)                       | -                             | -         | -          |
| matched (n=173)     |                            |                                 |                               |           |            |                             |                                 |                               |           |            |
| Severe or critical¶, n (%) | 117(86.7)                 | 28(53.8)                        | 5.34(1.87-15.30)              | 0.002     | 0.004      | 116(86.6)                   | 19(48.7)                       | 5.40(2.01-14.54)               | <0.001    | 0.003      |
| **DM + HTN**        |                             |                                 |                               |           |            |                             |                                 |                               |           |            |
| unmatched (n=100)   | 87(87)                      | 13(13.0)                        | -                             | -         | -          | 86(86.9)                    | 13(13.1)                       | -                             | -         | -          |
| matched (n=99)      |                            |                                 |                               |           |            |                             |                                 |                               |           |            |
| Severe or critical¶, n (%) | 81(93.1)                  | 10(76.9)                        | 5.54(2.00-15.34)              | 0.001     | 0.004      | 80(93)                      | 10(76.9)                       | 5.01(0.80-31.43)               | 0.085     | 0.339      |
| **DM alone**        |                             |                                 |                               |           |            |                             |                                 |                               |           |            |
| unmatched (n=140)   | 98(70)                      | 42(30.0)                        | -                             | -         | -          | 97(77)                      | 29(23)                         | -                             | -         | -          |
| matched (n=126)     |                            |                                 |                               |           |            |                             |                                 |                               |           |            |
| Severe or critical¶, n (%) | 89(90.8)                  | 24(57.1)                        | 5.19(1.29-20.87)              | 0.020     | 0.081      | 88(51.7)                    | 15(90.7)                       | 5.32(1.45-19.56)               | 0.012     | 0.047      |
| **HTN alone**       |                             |                                 |                               |           |            |                             |                                 |                               |           |            |
| unmatched (n=145)   | 123(84.8)                   | 22(15.2)                        | -                             | -         | -          | 122(84.7)                   | 22(15.3)                       | -                             | -         | -          |
| matched (n=144)     |                            |                                 |                               |           |            |                             |                                 |                               |           |            |
| Severe or critical¶, n (%) | 108(87.8)                 | 13(59.1)                        | 5.72(1.69-19.32)              | 0.005     | 0.020      | 107(87.7)                   | 13(59.1)                       | 5.279(1.60-17.47)              | 0.006     | 0.025      |

†Severe or critical defined according to WHO severity definition.
‡Odds ratio adjusted using logistic regression model with the following variables: age, sex, BMI, diabetes, hypertension, renal disease, number of comorbidities (that includes diabetes, hypertension, cardiovascular disease (heart failure/coronary artery disease), stroke, renal disease, asthma and obesity) and inpatient COVID-19 regimen.

For multiplicity correction, Bonferroni method was used to adjust the $P$ values.

DM: Diabetes; HTN: hypertension; CI: Confidence interval;
treatment based on our specifications and propensity scores, but in this process many cases from the control/or treatment will be discarded leading to three analytical approaches confirm the severity outcome. It is noteworthy, the research question of ACEI/ARB versus non-ACEI/ARB users and COVID-19 death. Thirdly, unlike other studies, we conducted three models to adjust for potential confounders with adjustment for multiplicity problem [47][52-55]. The denitions to capture the severity of the disease, all of which were significant except for the need for mechanical ventilation, length of stay, and in-hospital setting lends external validity to the study as these hospitals accommodate patients from all social backgrounds in Saudi Arabia. Secondly, we used multiple (GCC) region designated specically as national referral hospitals for complex COVID-19 patients that other hospitals in the country cannot manage. The retrospective study in Italy observed signicantly lower severity of COVID-19 illness among ACEI/ARB users [16][48]. Most of the above-mentioned studies with regards to greater COVID-19 disease severity [46][49]. In contrast, a large multicenter retrospective study in the United Kingdom (UK) and a single-center retrospective study in Italy observed significantly lower severity of COVID-19 illness among ACEI/ARB users [16][48]. Many of the patients in our study had comorbid hypertension, diabetes, and renal disease and therefore were being treated with ACEI/ARB agents. It is in these high-risk patients that we observed proportionately more of the severe COVID-19-associated outcomes, which is physiologically plausible. The renin angiotensin aldosterone system (RAAS) is reported to play a major role in the pathogenesis of type 2 diabetes and hypertension [37]. Over 30 different variants of the ACE2 gene reported in the Lieden open variation database (LOVD) [38]. Several studies showed a potential link between certain ACE2 variants and the development of cardiovascular diseases such as hypertension, while other reports find the evidence is inconclusive [41-43]. The high rates of comorbidities in our population may be linked to the existence of ACE2 polymorphism. In particular, the association between ACE insertion/deletion (I/D) polymorphism and the development of type 2 diabetes and hypertension was reported by Alsaikhan et al in 2017 in Saudi Arabian population [23]. Moreover, studies in Malaysian, Taiwanese, Iranian and Turkish populations reported similar findings [24-26][42]. The evidence that ACEI/ARB use in COVID-19 patients is associated with more severe COVID-19 disease is growing but still insufficient to be conclusive yet biologically plausible. One hypothesis is that SARS-CoV-2 uses ACE2 receptors for cellular entry and that, therefore, ACEI/ARB use can block the receptor and thus prevent viral attachment, entry and multiplication. In this hypothesis, ACEI/ARB use would ultimately improve patients’ outcomes. Conversely, and the hypothesis being evaluated more intensively, that continuous use of these medications may lead to over-expression of ACE2 receptors by a negative feedback mechanism and thus increase coronaviruses binding to target cells [11][43]. Whether the existence of genetic susceptibility to ACE2 polymorphism and ACEI/ARB use has an effect on COVID-19 severity or not is yet to be determined [44].

Despite the fact that the deﬁnitions of severity of COVID-19 disease need to be harmonized, the contradictory ﬁndings reported in different populations with regards to the severity of COVID-19 may suggest population differences [16-17][45-49]. For example, in a US study, Mehta et al. showed no signiﬁcant association between ACEI/ARB use and mortality, though it reported potential harmful effects with ACEI/ARB use including, higher hospital and ICU admissions [45]. Another study in France by Liabeuf et al and two studies in the United States by Rentsch et al. and Richardson et al reported signiﬁcant ﬁndings with regards to greater COVID-19 disease severity [46][49]. In contrast, a large multicenter retrospective study in the United Kingdom (UK) and a single-center retrospective study in Italy observed signiﬁcantly lower severity of COVID-19 illness among ACEI/ARB users [16][48]. Most of the above-mentioned studies deﬁned severity of COVID-19 illness as ICU admission rates [16][48]. Further, there could be an ethnicity signal certain populations are more susceptible to severe COVID-19 disease in association with ACEI/ARB use. In addition to our study in a high-risk Saudi population treated in tertiary referral hospitals, a large UK cohort study found that Black Africans on ACEI/ARB had a higher risk of COVID-19 disease [50]. Our population may be considered similar to a study conducted in Turkey [51] that found that ACEI/ARB use in hypertensive patients was independently associated with ICU admission, mechanical ventilation and in-hospital mortality.

Our study has several strengths and provides additional insights into the association of ACEI/ARB use and severity of COVID-19 disease as potentially mediated by ethnicity. First, to our knowledge, this is the ﬁrst retrospective study conducted in two public specialty hospitals in the Gulf Cooperation Council (GCC) region designated speciﬁcally as national referral hospitals for complex COVID-19 patients that other hospitals in the country cannot manage. The setting lends external validity to the study as these hospitals accommodate patients from all social backgrounds in Saudi Arabia. Secondly, we used multiple deﬁnitions to capture the severity of the disease, all of which were signiﬁcant except for the need for mechanical ventilation, length of stay, and in-hospital death. Thirdly, unlike other studies, we conducted three models to adjust for potential confounders with adjustment for multiplicity problem [47][52-55]. The three analytical approaches conﬁrm the severity outcome. It is noteworthy, the research question of ACEI/ARB versus non-ACEI/ARB users and COVID-19 severity presents a statistical challenge due to the fact that ACEI/ARB medications are indicated for particular set of patients that differs from control subjects. This will eventually lead to non-overlapping propensity score distributions. The PSM will model will try to ﬁnd close matches of the control and the treatment based on our speciﬁcations and propensity scores, but in this process many cases from the control/or treatment will be discarded leading to

### Table 4.

| Population                                    | Odds ratio (95% CI) | P value |
|-----------------------------------------------|---------------------|--------|
| DM or HTN or Renal disease (n=187)            | 1.44 (1.18-1.76)    | <0.001 |
| DM + HTN (n=100)                              | 1.37 (0.90-2.10)    | 0.138  |
| DM alone (n=140)                              | 1.33 (1.04-1.71)    | 0.023  |
| HTN alone (n=145)                             | 1.47 (1.13-1.91)    | 0.004  |

*Severe or critical defined according to WHO severity definition.

†Odds ratios were obtained after fitting a marginal structural model for average treatment effect using weights calculated from propensity scores. Robust sandwich type estimator was used to estimate confidence intervals. The following covariates were considered in the IPSW analysis: age, gender, diabetes, hypertension, renal disease, cardiovascular disease, body mass index, and asthma and number of comorbidities. For specifics, see Fig S3 on covariate selected and balance distribution.

DM: Diabetes; HTN: hypertension; CI: Confidence interval

**Discussion**

Our findings suggested that ACEI/ARB use can adversely affect the severity of COVID-19 illness as evident by the need of ICU admission, and non-invasive ventilation (suggesting more oxygen demand) in ACEI/ARB users. However, similar to the majority of reported studies, there was no association found in increase need of mechanical ventilation and in-hospital death [15][35-36]. Whether this is a general trend among ACEI/ARB users with COVID-19 or limited to some high-risk substrata is unclear and here our findings may prove relevant.

The odds ratios were calculated using a marginal structural model for average treatment effect using weights calculated from propensity scores. Robust sandwich type estimator was used to estimate confidence intervals. The following covariates were considered in the IPSW analysis: age, gender, diabetes, hypertension, renal disease, cardiovascular disease, body mass index, and asthma and number of comorbidities. For specifics, see Fig S3 on covariate selected and balance distribution.
decrease sample size and imprecise estimates. The IPSW circumvents this problem by utilizing all the available sample by assigning weights to observations. The balance can be achieved by creating pseudo-population in which treatment allocation is independent of observed covariates. In this analysis, extreme weights can be problematic and running weighted logistic regression may lead to variance inflation due to the fact that pseudo-population size may be inflated or deflated. In our analysis, we used stabilized weights and weights trimming was not necessary. The robust variance estimator from the “Survey” package gave us precise confidence intervals. We limited the IPSW analysis to a subset of the high population to which we think it’s safe to assume that this population will have an indication for ACEI/ARB use. All of the three analyses point towards higher odds of severity among ACEI/ARB users; especially in high risk patients. Due to the small sample size, the COVID-19 severity was not found in the diabetes and hypertension subset of patients. Both PSM and IPSW are very powerful tools for observational studies as means to reduce bias.

We recognize that the retrospective nature of this study is a limitation, though due largely because it was virtually impossible to mount a study when the hospitals were being overwhelmed with complex and severe cases of COVID-19. We could not stratify patients according to their chronicity of ACEI/ARB use because this information was not available. Notwithstanding the multiple models to adjust for confounding variables, we may have overlooked other variables that may explain the severity of COVID-19 disease. Some confidence intervals are wide and may limit the interpretability of some of the results. We could not assess the duration of non-invasive ventilation in patients on ACEI/ARB as compared to non-ACEI/ARB users. Lastly, our study did not differentiate between the two classes of antihypertensive agents (ACEI or ARB).

Clinically, a temporary ACEI/ARB withdrawal in COVID-19 patients with frequent blood pressure monitoring and management with other appropriate therapies maybe a prudent action especially for ICU patients where the risk is higher than the (short-term) benefit in the short term, until randomized controlled trials evaluate the impact of interim ACEI/ARB cessation in COVID-19 patients in the hospital setting. This may be viewed by some as a strong statement that goes against the mainstream recommendation to continue these medications [56]; however, our clinical experience is that a short-term ACEI/ARB withdrawal (≤2 weeks) strategy does not seem to increase the risk of cardiovascular disease deterioration in low-risk patients. Indirect evidence may be inferred from a randomized trial comparing ACEI (quinapril) continuation or withdrawal (by giving placebo) for 16 weeks in heart failure patients, which showed that heart failure symptoms worsened only after 4-6 weeks following ACEI withdrawal [57]. The two weeks strategy we propose as an interim clinical approach, though subject to formal evaluation in a clinical trial, might reduce the severity of COVID-19 disease, the need of ICU admission, and the need of oxygen through non-invasive ventilation. Admittedly, this debated question can be answered by well-designed RCTs. Until such trials as REPLACECOVID in the US, the BRACE-CORONA trial in Brazil, and the ACEI-COVID trial in Austria, that compare the effects of ACEI/ARB continuation or withdrawal in hospitalized COVID19 patients [58-60].

Conclusions

ACEI/ARB use was found to be associated with adverse effects on the severity of COVID-19 disease in Saudi Arabian patients, most of them with the comorbidities, singularly or concomitantly, of hypertension, diabetes, and renal disease. As compared to non-ACE/ARB users, ACEI/ARB users had higher disease severity and ICU admission and non-invasive ventilation. Notably, patients on ACEI/ARB with diabetes, hypertension and renal disease were at higher risk of developing severe COVID-19 disease compared to non-ACEI/ARB.

Abbreviations

ACEI: Angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; RAAS: Renin angiotensin aldosterone system; COVID-19: Coronavirus disease,2019; IPSW: Inverse propensity score weighting; PSM: Propensity score matching; ICU: Intensive care unit; OR: Odds ratio; WHO: World Health Organization; SARS-CoV-2: Severe acute respiratory syndrome coronavirus; MOH: Ministry of Health; NIV: Non-invasive ventilation; MV: Mechanical ventilation; RT-PCR: Real-time polymerase chain reaction (RT-PCR); LOVD:Lieden open variation database.

Declarations

Ethics approval and consent to participate

The Institutional Review Boards at KFMC and PMAH (IRB 20-200) approved the study. All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was waived since it was an exempt study conducting a retrospective analysis.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

Competing interests

The authors declare that they have no competing interests.

Funding

The authors would like to thank the Research Center at King Fahd Medical City, Riyadh, for their financial support provided for the manuscript.
Authors' contributions

SMBA and AAA conceptualized the study and reviewed the manuscript. TMK, IA, AA and NKA did the data acquisition, initial analysis and interpretation. ME, BA, NMA, YM, and MMA contributed for gathering of funding resources and data curation. WA, MAA, ASA, ABK, and MA wrote the first draft of the manuscript. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

Authors would like to thank the staff at Research Center of King Fahad Medical City and Prince Mohammed Bin Abdulaziz Hospital for their valuable contribution. The authors are also thankful to AlMaarefa University, Riyadh for providing support to do this research.

References

1. Lu et al., "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding," Lancet, vol. 395, no. 10224, pp. 565–574, 2020.
2. Zhu et al., "A novel coronavirus from patients with pneumonia in China, 2019," N. Engl. J. Med., 2020.
3. H. Organization, "WHO Coronavirus Disease (COVID-19) Dashboard," 2020. https://covid19.who.int/ (accessed Aug. 31, 2020).
4. Lotfi, M. R. Hamblin, and N. Rezaei, "COVID-19: Transmission, prevention, and potential therapeutic opportunities," Clin. Chim. Acta, 2020.
5. A. Al-Tawfiq, R. Leonardi, G. Fasoli, and D. Rigamonti, "Prevalence and fatality rates of COVID-19: What are the reasons for the wide variations worldwide?", Travel Med. Infect. Dis., 2020.
6. [6] Guan et al., "Clinical characteristics of coronavirus disease 2019 in China," N. Engl. J. Med., vol. 382, no. 18, pp. 1708–1720, 2020.
7. Li et al., "Age-dependent risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China," Front. Med., vol. 7, p. 190, 2020.
8. Caussy, F. Wallet, M. Laville, and E. Disse, "Obesity is associated with severe forms of COVID-19," Obesity, 2020.
9. Yang et al., "Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis," Int. J. Infect. Dis., 2020.
10. Zhou et al., "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study," Lancet, 2020.
11. Fang, G. Karakulaklis, and M. Roth, "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?", Lancet. Respir. Med., vol. 8, no. 4, p. e21, 2020.
12. Esler and D. Esler, "Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?," J. Hypertens., vol. 38, no. 5, pp. 781–782, 2020.
13. Zhang, J. M. Penninger, Y. Li, N. Zhong, and A. S. Slutsky, "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target," Intensive Care Med., vol. 46, no. 4, pp. 586–590, 2020.
14. Hoffmann, H. Kleine-Weber, N. Krüger, M. A. Mueller, C. Drosten, and S. Pöhlmann, "The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMRPSS2 for entry into target cells," BioRxiv, 2020.
15. Grover and M. Oberoi, "A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers," medRxiv, 2020.
16. Felice et al., "Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives," Am. J. Hypertens., 2020.
17. Liabeuf et al., "Association between renin–angiotensin system inhibitors and COVID-19 complications," Eur. Hear. Journal-Cardiovascular Pharmacother., 2020.
18. Plecher, "Saudi Arabia: Average age of the population from 1950 to 2050," Statista. https://www.statista.com/statistics/262482/median-age-of-the-population-in-saudi-arabia/ (accessed Sep. 01, 2020).
19. M. Al-Khaldi, E. A. Al-Ghamdi, T. I. Al-Mogbil, and H. I. Al-Khashan, "Family medicine practice in Saudi Arabia: The current situation and proposed strategic directions plan 2020," J. Family Community Med., vol. 24, no. 3, p. 156, 2017.
20. Abraham, S. Kurdi, and K. MacDonald, "The hypertension, diabetes and chronic kidney disease triangle in Arab countries," J. Hum. Hypertens., vol. 31, no. 6, p. 373, 2017.
21. Naeeem, "Burden of diabetes mellitus in Saudi Arabia," Int. J. Health Sci. (Qassim), vol. 9, no. 3, p. V, 2015.
22. Alwin Robert, M. Abdulaziz Al Dawish, R. Braham, M. Ali Musallam, A. Abdullah Al Hayek, and N. Hazza Al Kahtany, "Type 2 diabetes mellitus in Saudi Arabia: major challenges and possible solutions," Curr. Diabetes Rev., vol. 13, no. 1, pp. 59–64, 2017.
23. I. Al-Saikhan, M. A. Abd-Elaziz, and R. H. Ashour, "Association between risk of type 2 diabetes mellitus and angiotensin-converting enzyme insertion/deletion gene polymorphisms in a Saudi Arabian population," Biomed. Reports, vol. 7, no. 1, pp. 56–60, 2017.
24. M. Ghazali, A. Rehman, and A. R. A. Rahman, "Candidate gene polymorphisms and their association with hypertension in Malays," Clin. Chim. Acta, vol. 388, no. 1–2, pp. 46–50, 2008.
25. R. NIKZAMIR, M. Nakhjavani, T. Golmohamadi, and L. Dibai, "Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus," 2008.
26. Agachan, T. Isbir, H. Yilmaz, and E. Akoglu, "Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients," Exp. Mol. Med., vol. 35, no. 6, pp. 545–549, 2003.
27. E. Morra et al., “Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis,” Rev. Med. Virol., vol. 28, no. 3, p. e1977, 2018.

28. H. Organization and others, “Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020,” 2020.

29. Lee and D. K. Lee, “What is the proper way to apply the multiple comparison test?,” Korean J. Anesthesiol., vol. 71, no. 5, p. 353, 2018.

30. A. Stuart, G. King, K. Imai, and D. Ho, “Matchit: nonparametric preprocessing for parametric causal inference,” J. Stat. Softw., 2011.

31. C. Austin, “Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research,” Commun. Stat. Comput., vol. 38, no. 6, pp. 1228–1234, 2009.

32. Noah Greifer, “WeightIt: Weighting for Covariate Balance in Observational Studies,” 2020. https://cran.r-project.org/web/packages/WeightIt/index.html (accessed Oct. 23, 2020).

33. M. van der Wal, R. B. Geskus, and others, “ipw: an R package for inverse probability weighting,” J Stat Softw., vol. 43, no. 13, pp. 1–23, 2011.

34. J. Desai and J. M. Franklin, “Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners,” bmj, vol. 367, p. i5657, 2019.

35. Zhang, J. Yu, L. Pan, and H. Jiang, “ACE/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis,” Pharmacol. Res., p. 104927, 2020.

36. Alam and I. Abraham, “Mortality in COVID-19 patients treated with ACEIs/ARBs: re-estimated meta-analysis results following the Mehra et al. retraction,” Pharmacol. Res., 2020.

37. A. M. Jandeleit-Dahm, C. Tikkelli, C. M. Reid, C. I. Johnston, and M. E. Cooper, “Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes,” J. Hypertens., vol. 23, no. 3, pp. 463–473, 2005.

38. Global Variome shared LOVD, “Unique variants in gene ACE2,” 2008. https://databases.lovd.nl/shared/variants/ACE2/unique (accessed Jul. 27, 2020).

39. S. Pinheiro et al., “The combination of ACE I/D and ACE2 G8790A polymorphisms reveals susceptibility to hypertension: A genetic association study in Brazilian patients,” PLoS One, vol. 14, no. 8, p. e0221248, 2019.

40. Duru, S. Farrow, J.-M. Wang, W. Lockette, and T. Kurtz, “Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension,” Am. J. Hypertens., vol. 7, no. 8, pp. 759–762, 1994.

41. Yang, J. Zhao, L. Xing, and L. Shi, “The association between angiotensin-converting enzyme 2 polymorphisms and essential hypertension risk: A meta-analysis involving 14,122 patients,” J. Renin-Angiotensin-Aldosterone Syst., vol. 16, no. 4, pp. 1240–1244, 2015.

42. H. Tseng, C. P. Tseng, C. K. Chong, J. J. Sheu, and J. C. Cheng, “Angiotensin-converting enzyme gene polymorphism and stroke in type 2 diabetic patients in Taiwan,” Eur. J. Clin. Invest., vol. 37, no. 6, pp. 483–491, 2007.

43. H. Khan and S. K. Zaidi, “Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19,” Drugs Ther. Perspect., p. 1, 2020.

44. Lippi, C. J. Lavie, B. M. Henry, and F. Sanchis-Gomar, “Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?,” Clin. Chem. Lab. Med., vol. 1, no. ahead-of-print, 2020.

45. Mehta et al., “Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19),” JAMA Cardiol., 2020.

46. Richardson et al., “Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area,” JAMA, 2020.

47. Feng et al., “COVID-19 with different severities: a multicenter study of clinical features,” Am. J. Respir. Crit. Care Med., vol. 201, no. 11, pp. 1380–1388, 2020.

48. Bean et al., “ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COV2 infection in a multi-site UK acute Hospital Trust,” medRxiv, 2020.

49. T. Rentsch et al., “Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years,” MedRxiv, 2020.

50. Hippisley-Cox et al., “Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people,” Heart, 2020.

51. Selçuk et al., “Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?,” Clin. Exp. Hypertens., pp. 1–5, 2020.

52. Meng et al., “Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension,” Emerg. Microbes Infect., vol. 9, no. 1, pp. 757–760, 2020.

53. Yang et al., “Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study,” Hypertension, 2020.

54. Wang et al., “The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension,” Ann. Transl. Med., vol. 8, no. 7, 2020.

55. Liu et al., “Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients,” medRxiv, 2020.

56. Krahn, S. J. Bewick, C. M. Chow, B. Clarke, S. Cowan, and others, “Guidance from the CCS COVID-19 rapid response team,” Can. Cardiovasc. Soc., 2020.

57. W. Pflugfelder, G. Baird, M. J. Tonkon, R. DiBianco, B. Pitt, and others, “Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: A double-blind, placebo-controlled study of quinapril,” J. Am. Coll. Cardiol., vol. 22, no. 6, pp. 1557–1563, 1993.

58. gov, “Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID),” 2020. https://clinicaltrials.gov/ct2/show/NCT04338009 (accessed Jul. 27, 2020).
59. gov, "Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19 (BRACE-CORONA)." https://clinicaltrials.gov/ct2/show/NCT04364893 (accessed Jul. 27, 2020).
60. gov, "Stopping ACE-inhibitors in COVID-19 (ACEI-COVID)," 2020. https://clinicaltrials.gov/ct2/show/NCT04353596 (accessed Jul. 27, 2020).

Supplementary Materials

Table S1: Propensity Score-Matching (PSM) matching balance,

Table S2: The severity of COVID-19 disease based on WHO definition and classification among ACEI/ARB vs non-ACEI/ARB users based on WHO definition,

Figure S1: Propensity scores distribution (mirror diagram),

Figure S2: Love plot for the propensity score matching model-Covariates balance,

Figure S3: Love plot for IPSW-Covariates balance (A - Diabetes, hypertension or renal disease, B-hypertension and diabetes, C- Diabetes alone, D- Hypertension alone).

Figures

![Figure 1](https://example.com/figure1.png)

Study flow diagram. Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; COVID-19, coronavirus disease 2019

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarymaterial.docx](https://example.com/supplementarymaterial.docx)